Biotechs Befriend Non-Dilutive Funds

"Few have raised “non-dilutive” financing better than Achaogen Inc., an antibiotics developer. Because antibiotic resistance is a public-health problem, and because Achaogen’s drugs may also work against bio-terrorism threats like anthrax, the South San Francisco company has been able to supplement its $41 million in venture financing..."

Brian Gormley
The Wall Street Journal: Venture Capital Dispatch

Read article @ blogs.wsj.com

Achaogen Inc. takes aim at superbugs

"The war against hospital superbugs is turning nasty, and Kevin Judice wants his company on the front lines.

Achaogen Inc. started a Phase I trial Jan. 26 that focuses on next-generation antibacterials, which the company calls neoglycosides, to treat hospital-based infections. It could be “the big hammer,” CEO Judice said, against potential killer superbugs like methicillin-resistant Staphylococcus aureus, or MRSA."

Ron Leuty
San Francisco Business Times

Read article @ BizJournals.com